Neumeier Poma Investment Counsel LLC Supernus Pharmaceuticals, Inc. Transaction History

Neumeier Poma Investment Counsel LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$19.93 - $29.13 $11 Million - $16 Million	-550,676 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $10.4 Million - $13.6 Million	-406,725 Reduced 42.48%	550,676 $15.1 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $304,693 - $395,307	10,170 Added 1.07%	957,401 $31.7 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $14.8 Million - $19 Million	452,900 Added 91.62%	947,231 $33.2 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $711,509 - $1.14 Million	23,071 Added 4.9%	494,331 $16.4 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $1.92 Million - $2.55 Million	45,010 Added 10.56%	471,260 $23.7 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $4.28 Million - $5.81 Million	-97,100 Reduced 18.55%	426,250 $25.5 Million
Q1 2018 May 14, 2018	BUY	$37.15 - $46.9 $31,763 - $40,099	855 Added 0.16%	523,350 $24 Million
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $7.24 Million - $8.47 Million	-198,925 Reduced 27.57%	522,495 $20.8 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $26.5 Million - $35.8 Million	721,420	721,420 $28.9 Million

261

59.3M

47.9K

13.1K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.82B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Neumeier Poma Investment Counsel LLC, based on Form 13F filings with the SEC.

Stay updated on Neumeier Poma Investment Counsel LLC with notifications on news.